Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Flexible Dose Study of Very Low Doses of Naltrexone-Buprenorphine Transfer to Extend-Release Naltrexone (VIVITROL®) in Opioid Addiction

Next Previous
Trial Profile

An Open Label, Flexible Dose Study of Very Low Doses of Naltrexone-Buprenorphine Transfer to Extend-Release Naltrexone (VIVITROL®) in Opioid Addiction

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jun 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Naltrexone (Primary) ; Buprenorphine/naloxone
  • Indications Opioid-related disorders
  • Focus Therapeutic Use
  • Acronyms BUP/NXT-VIVI

Most Recent Events

  • 04 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
  • 26 Oct 2014 Planned End Date changed from 1 Sep 2015 to 1 Mar 2015 as reported by ClinicalTrials.gov record.
  • 26 Oct 2014 Planned primary completion date changed from 1 Sep 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top